Nonionic polyethylene glycol-ferrioxamine as a renal magnetic resonance contrast agent.
The MR relaxation properties of ferrioxamine-B, a chelate of iron, were investigated in vitro and in vivo to establish the potential use of the compound as a paramagnetic contrast agent. Whereas the paramagnetic relaxivity of ferrioxamine-B is such that, compared to gadolinium-DTPA (Gd-DTPA), two to three times higher concentrations are necessary to produce the same relaxation effects, the toxicity of the iron ion should be much lower because of the availability of physiological metabolic pathways. Preliminary experiments in three dogs under invasive cardiovascular monitoring demonstrated that high-dose bolus application (0.1-0.3 mmol/kg body weight) of ferrioxamine-B leads to a precipitous blood pressure drop to almost zero, lasting for several minutes. This reaction seems most likely the result of a negative inotropic effect of ferrioxamine-B. In order to reduce these side effects ferrioxamine was modified to a nonionic derivative, PEG-ferrioxamine-B. In vivo experiments with this compound did not demonstrate any substantial change in blood pressure. Dynamic MR imaging of the kidneys and the liver was performed after bolus injection of the compound in six dogs. The results indicate that PEG-ferrioxamine-B produces effects very similar to Gd-DTPA, resulting in T1-mediated signal intensity increases in the liver and in the early stages of passage through the kidneys. During the phase of medullary concentration, T2 effects seem to dominate visualization of the renal medulla. The nonionic PEG-ferrioxamine-B derivative appears to offer an alternative to gadolinium-containing chelates as an MR contrast agent.
Duewell
S
S
Department of Medical Radiology, University Hospital Zurich, Switzerland.
Wüthrich
R
R
von Schulthess
G K
GK
Jenny
H B
HB
Muller
R N
RN
Moerker
T
T
Fuchs
W A
WA
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003287:Contrast Media / Q000494:pharmacology; D003676:Deferoxamine / Q000494:pharmacology / Q000031:analogs & derivatives; D004285:Dogs; D005290:Ferric Compounds / Q000494:pharmacology; D006321:Heart / Q000187:drug effects / Q000502:physiology; D007668:Kidney / Q000033:anatomy & histology*; D008279:Magnetic Resonance Imaging; D011092:Polyethylene Glycols / Q000494:pharmacology
D003287:Contrast Media; D005290:Ferric Compounds; C067085:polyethylene glycol ferrioxamine; D011092:Polyethylene Glycols; C002577:ferrioxamine B; D003676:Deferoxamine